EPCAM and neoplasm: In contrast, bispecific CAR-T cells targeting both EpCAM and ICAM - 1 showed enhanced antitumor activity, with the ability to prevent resistance and reduce relapse driven by heterogeneous or EpCAM-negative tumor subpopulations (45).